Action of rare earth metal complexes on neurogenic as well as on bradykinin-induced inflammation.
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D000925:Anticoagulants / Q000494:pharmacology*; D000997:Antivenins; D001777:Blood Coagulation; D001920:Bradykinin / Q000037:antagonists & inhibitors*; D002396:Catechols / Q000494:pharmacology*; D004396:Coloring Agents; D003228:Conjunctiva / Q000187:drug effects; D003533:Cyproheptadine / Q000494:pharmacology; D004558:Electric Stimulation; D005143:Eyelids / Q000187:drug effects; D005439:Flufenamic Acid / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D007249:Inflammation / Q000139:chemically induced; D007610:Kallikreins / Q000037:antagonists & inhibitors; D009354:Neodymium / Q000494:pharmacology*; D010653:Phenylbutazone / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D012980:Sodium Salicylate / Q000494:pharmacology
D000893:Anti-Inflammatory Agents; D000925:Anticoagulants; D000997:Antivenins; D002396:Catechols; D004396:Coloring Agents; D009354:Neodymium; D003533:Cyproheptadine; D005439:Flufenamic Acid; D007610:Kallikreins; D010653:Phenylbutazone; D001920:Bradykinin; D012980:Sodium Salicylate; D007213:Indomethacin